Register
Journal Updates
eMediNexus Coverage from: 
Metformin Repurposed: Boosts Survival in TKI-Treated Lung Cancer
eMediNexus,  10 September 2019
remove_red_eye 575 Views
#Hematology #Oncology #Pharmacist #Radiology

1 Read Comments                

Adding metformin to standard inhibitors of epidermal growth factor receptor (EGFR) and tyrosine kinase inhibitors (TKIs) significantly improved both progression-free and overall survival in advanced lung adenocarcinoma – with no significant increase in adverse events, a randomized phase II study found.

Investigators found a significantly longer median progression-free survival with EGFR-TKIs plus metformin: 13.1 months (95% CI 9.8-16.3) compared with 9.9 months (95% CI 7.5-12.2) for standard EGFR-TKIs (hazard ratio 0.60, 95% CI 0.40-0.94, P=0.03). The median overall survival was also significantly longer for patients receiving combination therapy: 31.7 months (95% CI 20.5-42.8) vs 17.5 months (95% CI 11.4-23.7, P=0.02). The findings are published in JAMA Oncology.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now